In many types of cancer, the existence of AHR agonists has been demonstrated that can augment the expression of inflammatory mediators (Miller et al. 2005), MMPs (Peng et al. 2009a; Ishida et al. 2010), and transcriptional regulators (Pierre et al. 2014) in a genomic pathway, which leads to downregulation of cell adhesion and upregulation of migration and invasion. The gene discussed is AHR; the disease is cancer.